Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Interventional × brolucizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 2 1 Macular Degeneration 1

Interventions

Cyclophosphamide 357 Carboplatin 302 pembrolizumab 281 Cisplatin 281 Gemcitabine 279 Radiotherapy 265 Paclitaxel 263 Docetaxel 254 Bevacizumab 223 Rituximab 210 Capecitabine 200 Nivolumab 190 Dexamethasone 182 Fluorouracil 176 fludarabine 163 Oxaliplatin 157 Doxorubicin 139 Irinotecan 134 Leucovorin 132 Etoposide 130 Pemetrexed 128 Cytarabine 124 Bortezomib 116 fludarabine phosphate 114 Lenalidomide 110 Filgrastim 110 Erlotinib Hydrochloride 107 Cetuximab 107 Temozolomide 102 Radiation 97

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03710564 2023-01-30

MERLIN

Novartis

Phase 3 Terminated

535 enrolled 14 charts

Macular Degeneration, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡